




Acta Dermatovenerol Croat                              2018;26(2):183-185                               LETTER TO THE EDITOR
Dear	Editor,
There are few literature data about nevi in patients 
with a history of toxic epidermal necrolysis (TEN) and 
little recommendations for follow-up and risks of 
melanoma (MM). Eruptive melanocytic nevi (EMN) 
is a rare phenomenon that has been associated with 
bullous disorders, immunosuppression, and immuno-
deficiency, but in some cases can occur without pre-
cipitating factors (1). The etiology is largely unknown, 
but there is evidence that immunosuppression might 
play a crucial role in nevogenesis, probably due to the 
inability of the immune system to inhibit melanocytic 
(MC) proliferation (2,3). We report the follow-up of 
a patient with a history of TEN who later developed 
atypical nevi.
A 17-year-old man with a history of severe TEN 
two years earlier, most probably due to valproic acid 
and diclofenac, was referred to our Department due 
to atypical nevi. The patient presented with scars, 
scattered pigmentation (Fig. 1), and symblepharon 
as a consequence of TEN (Fig. 2). Most of his nevi de-
veloped in following two years after TEN. During the 
first visit in 2009, clinical and dermoscopic photod-
ocumentation was performed. The patient presented 
with a moderate number of nevi (Fig. 3), dermoscopi-
cally subclassified as globular. One atypical MN was 
found on the back, with dermoscopic findings of 
reticular pattern and presence of suspected areas of 
regression (Fig. 4. a, b), and it was excised to rule out 
melanoma (Fig. 4, Fig. 5). The patient did not come to 
regular follow-up from 2009 to 2014, and presented 
in 2014 which was when comparative photo docu-
mentation was made. As this visit another, speckled 
type of newly-occurred nevus was excised. Both ex-
cised nevi were histopathologically characterized as 
dysplastic. 
Only a few references are available on nevi de-
velopment after TEN. Anticonvulsives and NSAIDs, 
as in our case, are often involved in the etiopatho-
genesis of TEN (4,5). Survivors may experience a va-
riety of long-term complications; authors reported 
Figure	1. Detail from the skin of the patient on the back, 
with scarring and postinflammatory residual scattered hy-
per- and hypopigmentation, and atypical nevus.  
Figure	2. Patient presenting with symblepharon.
Figure	3. Patient presented with few to a moderate number of nevi.
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that 19% of their patients developed new nevi after 
TEN (6,7). EMN develop several years after TEN as a 
suddenly arising large number of nevi that may re-
semble speckled lentiginous nevi (8). Histologically. 
EMN demonstrate a proliferation of MC at the dermo-
epidermal junction and, if compound, in the papil-
lary dermis, arranged mostly in nests. Junctional MC 
may appear slightly pleomorphic, but no significant 
cytological atypia or prominent pagetoid spread of 
MC was reported (9). EMN have been associated with 
a specific dermoscopic finding of a symmetrical pe-
ripheral rim of globules which represent pigmented 
junctional nests of MC in the periphery and are a spe-
cific feature of rapidly enlarging MC nevi (10,11). The 
pathogenesis of EMN is not known. The microenvi-
ronment of epidermal regeneration may have some 
effects on MC because MC hyperplasia develops after 
cutaneous trauma (observed in recurrent nevi). The 
cytokines and growth factors produced and secreted 
during epidermal regeneration might contribute to 
the proliferation of residual epidermal MC and subse-
quent nevus formation (12). Because most of the bul-
lous disorders associated with EMN are transient, the 
authors believe that changes in local growth factors 
may also be temporary and MN remain stable without 
a propensity to malignant degeneration without fur-
ther stimuli (13). This is corroborated by the fact that 
no reports of malignant change of EMN in patients 
with bullous disorders have been described. It is likely 
that the etiology and natural course of EMN differs 
between two main populations of patients, with EMN 
arising after bullous disorders being more likely to re-
main benign compared with those with ongoing im-
munosuppression, but this hypothesis has yet to be 
proven. The actual risk of MM in patients with EMN re-
mains unknown. Since our patient did not have many 
nevi, he does not fit into the EMN category. Due to 
the atypical appearance of his nevi, long-term follow-
up on 6-month basis is recommended.
Figure	4. (a, b) Atypical nevus on the back of the patient, 
clinical and dermoscopic view. Dermoscopy showed com-
bination of reticular structure, nonspecific areas of erythe-
ma, peppering and milky red color. Excision was made due 
to need to rule out melanoma (Delta Heine, ×10 magnifica-
tion, Nikon Coolpix). Biopsy showed nests of nevus cells in 
the basal layers of the epidermis, merging of a few nests, 
and lymphocytic response around the blood vessels in the 
papillary dermis. Consequently, diagnosis of dysplastic ne-
vus was established.
Figure	5. Speckled appearance of nevus, dermoscopically a combination of globules and nonspecific structure arranged in 
a speckled way, histopathologic diagnosis of dysplastic nevus was established after excision.
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